Intravitreal Bevacizumab (Avatin) for Choroidal Neovacularization econdary to Central erou Chorioretinopathy, econdary to Punctate Inner Choroidopathy, or of Idiopathic Origin Original Reearch Article

Purpoe To evaluate the afety and efficacy of intravitreal bevacizumab in the treatment of idiopathic choroidal neovacularization (CNV) and CNV econdary to central erou chorioretinopathy (CC) or punctate inner choroidopathy (PIC). Deign Propective, nonrandomized, interventional cae erie. Method In an intitutional clinical practice, 15 patient were recruited; nine had idiopathic CNV, two had CNV econdary to CC, and four had CNV attributable to PIC. Patient received three monthly 1.25-mg intravitreal bevacizumab injection for three month. Patient were followed for ix month, and the bet-corrected viual acuity (BCVA), fluorecein angiography (FA) finding, and optical coherence tomography (OCT) central foveal thickne (CFT) were aeed. Reult At baeline, the mean logMAR BCVA wa 0.48 (nellen equivalent = 20/60). The mean logMAR BCVA improved ignificantly to 0.25 (nellen equivalent = 20/36) and 0.17 (nellen equivalent = 20/30) at one and ix month, repectively (both P = .001). The mean OCT CFT reduced from 306 μm at baeline to 201 μm at ix month (P < .001). All eye (100%) had viual improvement of 1 line or more at ix month, and 11 (73.3%) improved by 2 or more line. FA howed abence of CNV leakage, the angiographic end point, at three month, and no recurrence wa oberved at ix month in all eye. No ytemic or ocular advere event were encountered. Concluion Intravitreal bevacizumab injection reulted in viual and anatomic improvement in eye with idiopathic CNV and CNV attributable to CC or PIC. Further tudie are warranted to ae the long-term afety and the regimen for optimal efficacy of intravitreal bevacizumab.